Rigel Pharmaceuticals (RIGL) Operating Expenses (2010 - 2026)

Rigel Pharmaceuticals' Operating Expenses history runs 17 years deep, the most recent figure standing at $46.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 15.71% year-over-year to $46.9 million in Q1 2026; TTM through Mar 2026 was $175.2 million, a 10.08% increase from a year earlier, with the FY2025 full-year figure at $168.8 million, up 8.85% from the prior year.
• Operating Expenses rose to $46.9 million in Q1 2026 per RIGL's latest filing, from $46.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $49.2 million in Q4 2022 and bottomed at $32.2 million in Q2 2023.
• The 5-year median for Operating Expenses is $40.8 million (2022), against an average of $40.2 million.
• Across the five-year window, Operating Expenses sank 31.25% in 2023 and rose 26.54% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $49.2 million in 2022, then sank by 31.25% to $33.8 million in 2023, then advanced by 21.03% to $40.9 million in 2024, then gained by 13.9% to $46.6 million in 2025, then gained by 0.65% to $46.9 million in 2026.
• Per Business Quant, the three latest RIGL Operating Expenses figures stand at $46.9 million (Q1 2026), $46.6 million (Q4 2025), and $41.0 million (Q3 2025).